This post was originally published on this site
Biogen announced earnings per share of $8.84 on revenue of $3.38B. Analysts polled by Investing.com anticipated EPS of $8.07 on revenue of $3.34B.
Biogen shares are down 9% from the beginning of the year, still down 28.77% from its 52 week high of $374.99 set on February 5. They are under-performing the Nasdaq 100 which is up 33.72% from the start of the year.
Biogen’s report follows an earnings beat by J&J on October 13, who reported EPS of $2.2 on revenue of $21.08B, compared to forecasts EPS of $1.98 on revenue of $20.2B.
Thermo Fisher Scientific had beat expectations on Wednesday with third quarter EPS of $5.63 on revenue of $8.52B, compared to forecast for EPS of $4.31 on revenue of $7.65B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
